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Introduction:Ovarian follicle growth is a key step in the success of assisted reproductive
treatment, but limited data exists to directly relate follicle growth to recombinant FSH
(rFSH) dose. In this study, we aim to evaluate FSH requirements for follicular growth
during controlled ovarian stimulation.
Method: Single center retrospective cohort study of 1,034 IVF cycles conducted
between January 2012–January 2016 at Hammersmith Hospital IVF unit, London, UK.
Median follicle size after 5 days of stimulation with rFSH and the proportion of antral
follicles recruited were analyzed in women treated with rFSH alone to induce follicular
growth during IVF treatment.
Results: Starting rFSH dose adjusted for body weight (iU/kg) predicted serum FSH level
after 5 days of rFSH (r2 = 0.352, p< 0.0001), median follicle size after 5 days of rFSH, and
the proportion of antral follicles recruited by the end of stimulation. Day 5 median follicle
size predicted median follicle size on subsequent ultrasound scans (r2 = 0.58–0.62;
p < 0.0001), and hence time to oocyte maturation trigger (r2 = 0.22, P < 0.0001).
Insufficient rFSH starting dose that required >5% dose-increase was associated with
increased variability in follicle size on the day of oocyte maturation trigger, and negatively
impacted the number of mature oocytes retrieved.
Conclusion: Weight-adjusted rFSH dose correlates with follicular growth during ovarian
stimulation. Early recruitment of follicles using a sufficient dose of rFSH from the start
of stimulation was associated with reduced variability in follicle size at time of oocyte
maturation trigger and an increased number of mature oocytes retrieved.
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INTRODUCTION
IVF treatment is increasingly used to help subfertile couples to conceive, with the number of cycles
carried out annually increasing by∼5% per year (1). However, 7.1% of cycles commenced in the UK
did not result in retrieval of oocytes and no embryos were formed in 11.9% of cycles (2). A key factor
in the success of assisted reproductive treatments is the induction of sufficient follicular growth by
recombinant FSH (rFSH) administration, whilst concurrently avoiding excessive stimulation that
could lead to an uncontrolled response.
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In the physiological human menstrual cycle, a small (∼30%)
rise in serum FSH level, due to reduced estradiol negative
feedback during the follicular phase (3), is sufficient to initiate
growth of the most sensitive ovarian follicles (4, 5). As follicles
grow, they produce estradiol and inhibin B, which negatively
feedback on FSH secretion to restrict the “FSH window”—
the period during which the FSH level remains above the
threshold to prevent atresia of non-dominant follicles (4–7). In
IVF cycles, a supraphysiological dose of rFSH is administered
to maintain serum FSH levels above this threshold, to extend
the FSH-window and promote multi-follicular growth (8, 9).
An insufficient dose of rFSH negatively impacts on the number
of follicles recruited and thus the number of oocytes retrieved.
Conversely, an excessive dose of rFSH can lead to over-
recruitment of follicles, increasing the risk of the potentially life-
threatening complication ovarian hyperstimulation syndrome
(OHSS), if hCG is used to induce oocyte maturation (10). Hence,
appropriate rFSH dosing is regarded as a key treatment decision
affecting both the success and safety of IVF treatment (11).
Selecting the optimal starting dose of rFSH is challenged
by the interindividual variation in response to the same dose.
Clinicians use clinical experience as well as baseline variables
such as age, antral follicle count (AFC), serum anti-Mullerian
hormone (AMH), body mass index (BMI), and follicular phase
serum FSH level in selecting an appropriate rFSH dose in
patients presenting for their first treatment cycle (12, 13). Due
to the variability in response, a dominant factor in choosing
rFSH dose in patients presenting for a second IVF cycle is the
ovarian response in a previous cycle (12, 14). The starting dose
of rFSH usually ranges between 100 and 450 IU, with 150 IU
being recommended for the average-responder. Algorithms and
nomograms to predict the number of oocytes retrieved have
been developed to help clinicians choose the appropriate starting
rFSH dose (11, 12, 14–17). The CONSORT algorithm takes into
account age, BMI, follicular phase serum FSH and AFC to predict
the number of oocytes retrieved in normo-ovulatory women aged
< 35 years, treated with a GnRH agonist co-treated stimulation
protocol (17). The PIVET algorithm recommends a rFSH starting
dose based on age and AFC with adjustment for AMH, BMI,
smoking and pre-treatment serum FSH level aiming to yield 8–12
oocytes in all women (11).
The majority of dosing algorithms relate rFSH dose to the
number of oocytes retrieved, which assumes a homogenous
response to the trigger of oocyte maturation (17). However,
additional factors such as follicle size on the day of trigger,
interval between trigger to oocyte retrieval and endocrine
response to trigger also influence the number of oocytes
retrieved, over and above response to rFSH dose (18). Antral
follicle count (AFC) can be regarded as an estimate of the follicle
pool that could respond to rFSH stimulation. Thus, researchers
have evaluated the success of follicular growth in relation to
AFC by calculating the “follicular output rate” (FORT) (i.e.,
number of follicles of 16–22mm on the day of trigger expressed
as a percentage of AFC) (19, 20). Others have reported the
“follicle to oocyte index (FOI),” which is the number of oocytes
expressed as a proportion of the antral follicle count (21).We
have previously reported that follicles of 12–19mm on the day
of trigger are most likely to yield mature oocytes (22). Thus, in
the current study we evaluated whether the starting rFSH dose
predicted the proportion of antral follicles that resulted in follicles
of 12–19mm by the end of stimulation and investigated the
relationship between rFSH dose and follicular growth during
ovarian stimulation in 1,034 IVF cycles.
MATERIALS AND METHODS
We performed a single-center retrospective cohort study
evaluating data-records from 1,034 GnRH antagonist co-treated
IVF cycles. The study was conducted at the Wolfson Fertility
Centre, Hammersmith Hospital, UK, between January 2012
and January 2016 (inclusive) in patients who had ovarian
stimulation by Gonal F (Merck Serono, Geneva, Switzerland).
Exclusion criteria were: use of additional/alternative medications
for ovarian stimulation including urinary FSH, recombinant LH,
or long-acting FSH preparations, or missing data on rFSH doses.
Women were not excluded for having PCOS, endometriosis or
for meeting Bologna/Poseidon criteria (23–25). A subset of cycles
(n = 175) were completed during clinical trials investigating the
use of kisspeptin as an oocyte maturation trigger and had more
intensive monitoring of endocrine values such as serum FSH and
LH during ovarian stimulation (26–28).
Baseline demographic data such as height, weight, ethnicity,
pre-treatment serum FSH (iU/L), LH (iU/L), AMH (pmol/L),
estradiol (pmol/L) and total AFC on transvaginal ultrasound
were collated. For the vast majority of patients, follicular phase
AFC and FSH measurements occurred within 3 months of
commencing stimulation. AFC was measured manually using
2D ultrasound. Follicle sizes were assessed by transvaginal
ultra-sonographic measurement (Toshiba Xario Prime,
Crawley, UK) conducted by up to nine experienced IVF
physicians/ultrasonographers at Hammersmith IVF unit over
the 4-year study period. The unit protocol is to conduct an
ultrasound scan after 4–5 days of rFSH. Starting doses of rFSH
(between 100 IU and 450 IU daily) were selected based on age,
AFC and physician experience. Patients may have had either
fixed (day 5 of rFSH) or flexible start (lead follicle of 14mm)
of GnRH antagonist administration due to a change in unit
policy during the time of the study. Two thirds of patients
started GnRH antagonist on day 5 of rFSH, 10% on day 7–8,
11% on day 9, and 13% on days 10–12. We collated data on
rFSH doses throughout ovarian stimulation, follicle counts and
sizes at each monitoring ultrasound scan. All follicle diameters
at each scan were individually recorded and a median follicle
size was calculated. Follicle sizes <6mm in diameter were
recorded as measuring 5mm during analysis. Preliminary linear
regression analysis suggested that an age of 35 years represented
an inflection point for response to rFSH. Evaluation of follicular
response following rFSH was assessed both in a subset of patients
with predicted ‘good response’ (age 18–34 years and AFC >15)
and those with predicted “poorer response” (age ≥35 years and
AFC ≤15). Remaining patients were classified as intermediate
responders (either age 18–34 years and AFC ≤15 or age ≥35
years and AFC >15).
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Study Approval
Patients who received kisspeptin to trigger oocyte maturation
from randomized clinical trials approved by the Hammersmith
and Queen Charlotte’s Research Ethics Committee, London, UK
(26–28). The trials were registered on the National Institutes of
Health Clinical Trials database (NCT01667406) and performed
in accordance with the Declaration of Helsinki. All patients
included in the study were treated at the IVF Unit at
Hammersmith Hospital, London, UK, under a license from the
UK Human Fertilization and Embryology Authority.
IVF Stimulation Protocol
Recombinant FSH (rFSH) (100–450 IU Gonal F, Merck Serono,
Geneva, Switzerland) was used to induce follicular growth.
Gonal F was started from day 2 or 3 in GnRH antagonist co-
treated ICSI cycles. Premature ovulation was prevented by a
GnRH antagonist- either cetrorelix (0.25mg, Cetrotide, Merck
Serono, Middlesex, UK) or ganirelix (0.25mg Orgalutran, Merck
Sharp & Dohme Ltd, Hertfordshire, UK). The trigger was
administered once 3 ovarian follicles were ≥18mm in diameter
and oocyte retrieval was conducted 36 h thereafter. The trigger
of oocyte maturation was either hCG, choriogonadotrophin
alpha (0.25mg, Ovitrelle; Merck Serono, Feltham, UK), GnRH
agonist—buserelin acetate (2mg, Suprecur, Sanofi-Aventis,
Guildford, UK), or kisspeptin-54 (6.4–12.8 nmol/kg as a single
bolus, or 19.2 nmol/kg as a split-dose over 10 h, Bachem Holding
AG, Bubendorf, Switzerland) administered subcutaneously (26–
28). Data from only one IVF cycle per woman was used during
the analysis.
Assays Used
Serum LH, FSH, estradiol, and progesterone were measured
using automated chemiluminescent immune immunoassays
(Abbott Diagnostics, Maidenhead, UK). Interassay coefficients
of variation were as follows: LH, 3.4%; FSH, 3.5%; estradiol,
3.4%; progesterone, 1.8%. Limits of detectability for each assay
were as follows: LH 0.07 mIU/ml; FSH 0.05 mIU/ml; estradiol
70 pmol/l (19 pg/mL); progesterone 0.3 nmol/L (0.1 ng/mL).
AMH was measured using an enzyme linked immunosorbent
assay (Beckman Coulter Inc, Brea, CA, USA). The reference
TABLE 1 | Baseline characteristics.
All cycles Potential to respond to rFSH P-value
Good responders
(AFC >15 & age 18–34 years)
Intermediate responders
(either AFC≤15 or age ≥35 yrs)
Poorer responders
(AFC≤15 & age ≥35 yrs)
n 1,034 354 497 183 -
Age (years) 35 [32–39] 32 [30–33] 38 [36–41] 40 [38–43] <0.0001
Weight (kg) 63.9 [56.7–71.9] 63.9 [56.5–70.0] 63.5 [57.0–72.1] 63.0 [55.0–72.0] 0.96
BMI (kg/m2) 23.7 [21.5–27.0] 23.8 [21.8–27.1] 23.6 [21.3–27.3] 24.0 [21.0–26.0] 0.65
Starting rFSH dose (iU) 150.0 112.5 150.0 300.0 <0.0001
[112.5–187.5] [112.5–150] [112.5–150] [225–300]
Starting rFSH dose per kg (iU/kg) 2.20 [1.80–2.8] 1.95 [1.66–2.30] 2.25 [1.85–2.78] 4.05 [3.13–5.00] <0.0001
Total Antral Follicle Count (AFC) 25 [17–34] 30 [24–40] 26 [20–34] 10 [7–13] <0.0001
Number of oocytes 12 [8–17] 12 [9–17] 12 [9–18] 7 [4–11] <0.0001
Number of mature oocytes 9 [6–13] 10 [7–14] 10 [7–14.5] 6 [3–8] <0.0001
Number of zygotes 7 [4–10] 8 [4–11] 7 [4–10] 4 [2–6] <0.0001
Clinical Pregnancy Rate (%) 50.2% 54.5% 52.2% 39.5% 0.006
Live Birth Rate (%) 40.1% 45.9% 41.9% 28.2% 0.001
Median follicle
size (mm)
Day 4 6.0 [6.0–7.0] 6.0 [5.3–6.0] 6.8 [6.0–7.5] 7.0 [5.5–7.5] 0.0011
Day 5 7.0 [6.0–8.0] 7.0 [6.0–8.0] 7.0 [6–8.5] 8.3 [7.0–10.0] <0.0001
Day 7 9.0 [8.0–11.0] 9.0 [7.0–10.5] 9.0 [8.0–11.0] 10.3 [9.0–12.0] 0.0003
Day 9 12.0 [10.0–13.0] 11.0 [10.0–13.0] 12.0 [10.0–13.0] 13.0 [11.0–14.0] <0.0001
Follicle count on final scan 23.0 [16.0–32.0] 27.0 [21.0–36.0] 24.0 [18.0–33.0] 12.0 [8.0–17.0] <0.0001
Day 5 serum estradiol (pmol/L) 1131 [672–1958] 918 [545–1677] 1276 [710–2064] 1099 [642–1767] 0.015
Ethnicity Afro-Caribbean 62 (6.0%) 14 (4.1%) 31 (6.7%) 11 (6.4%) -
Caucasian 530 (51.0%) 190 (56.9%) 243 (52.0%) 97 (56.1%) -
Middle Eastern 14 (1.0%) 6 (1.8%) 8 (1.7%) 0 -
East Asian 14 (1.0%) 1 (0.3%) 8 (1.7%) 5 (2.9%) -
South Asian 312 (31.0%) 107 (32.0%) 152 (32.6%) 54 (31.2%) -
Other 101 (10.0%) 16 (4.8%) 24 (5.2%) 6 (3.5%) -
Median [IQR] for continuous variables and number (%) for categorical variables of baseline characteristics are presented for all GnRH antagonist co-treated cycles (n = 1034). These
are further subdivided into predicted “good responders” (antral follicle count (AFC) >15 and age 18–34 years; n = 354), “intermediate responders” (AFC ≤15 or age ≥35; n = 497)
and “poorer responders” (AFC ≤15 and age ≥35 years; n = 183). Groups were compared by the Kruskal Wallis test. Categorical variables are presented as count (percentage; %)
and compared by the Chi squared Test. Font in italics denotes significance.
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range was 2.2–48.5 pmol/L (0.3–6.8 ng/mL). The lower limit of
detection was 0.6 pmol/l (0.08 ng/mL). The interassay coefficient
of variation was 4.6%; the intraassay coefficient of variation
was 4.0%.
Statistical Analysis
Statistical analysis was performed using GraphPad PRISM
version 7.0, STATA version 14.0 and R version 3.5.1. D’Agostino
& Pearson normality test was used to assess data distribution.
Normally distributed data is presented as mean ±standard
deviation (SD), and non-parametric data as median with
interquartile range (IQR). Non-parametric paired data for
two groups was compared by the Wilcoxon signed rank
test. Non-parametric unpaired data with two groups was
compared using Mann-Whitney U test. For parametrically
distributed data with multiple groups, one-way analysis of
variance (ANOVA) was used, whereas for non-parametrically
distributed data, the Kruskal-Wallis test was used. Simple
linear regression modeling was performed with Pearson
correlation coefficients for parametrically distributed data
and Spearman correlation coefficients for non-parametrically
distributed data. Categorical variables are presented as count
(percentage; %). Multivariate generalized linear regression was
used to assess the relationship between dose of Gonal F and
follicular growth with the following variables assessed: age,
AFC and pre-treatment serum FSH level. R2 coefficients of
determination were derived using the formula R2 = 1 – (residual
deviance)/(null deviance). A p < 0.05 was regarded as signifying
statistically significance.
RESULTS
Baseline Characteristics
Overall, 1034 GnRH antagonist co-treated cycles were included,
including 354 predicted “good responders” (age 18–34 years and
AFC >15) and 183 predicted “poor responders” (AFC≤15 & age
≥35 years; Table 1). As serum FSH and LH are not routinely
measured in IVF/ICSI cycles, this data was only available in a
subset of patients triggered with kisspeptin (n= 175).
Dose-Adjustments
Of the 1,034 GnRH antagonist co-treated cycles included, 270
(26%) had an average rFSH dose during treatment that was at
least 5% higher compared to the starting dose and 82 (8%) had
an average dose that was at least 5% lower than the starting dose,
whereas the remaining 682 (66%) received an average dose within
±5% of the starting dose.
Serum FSH and Follicular Growth
Serum FSH level at steady-state measured after 5 days of
rFSH administration was associated with median follicle size on
ultrasound (Figure 1A). Serum FSH levels were predicted by
rFSH dose-adjusted for body weight (r2 = 0.352, P < 0.001;
Figure 1B). Recombinant FSH dose-adjusted for body weight (IU
per kg) thus also predicted median follicle size following 5 days of
FIGURE 1 | Relationship between serum FSH level and follicle growth. Serum AMH and FSH levels were available in a subset of patients triggered with kisspeptin
(serum AMH >10 pmol/L; n = 147). (A) Mean (±SD) of median follicle size on ultrasound by categories of steady state serum FSH levels (iU/L) at 5 days after starting
recombinant FSH dose (rFSH) is presented (n = 144; A). Categories were compared by one-way ANOVA with post hoc Tukey’s multiple comparisons test. (B) Dose of
rFSH adjusted for body weight (iU/kg) predicted serum FSH level (n = 166) by simple linear regression: Day 4–5 serum FSH level = 2.79 x starting rFSH dose (iU/kg)
+ 1.8, r2 = 0.352, p < 0.0001. (C) Mean (±SD) of median follicle size on ultrasound by categories of starting rFSH adjusted for weight (iU/kg) at 5 days after starting
rFSH is presented (n = 147). Categories were compared by one-way ANOVA with post hoc Tukey’s multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001.
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FIGURE 2 | Effect of starting rFSH dose on follicle growth in predicted “good responders” (AFC>15 and age 18–34 years; n = 354). (A) Mean (±SD) starting Gonal
F/kg is positively associated with median follicle size on ultrasound (mm) after 5 days of rFSH treatment. Categories were compared by one-way ANOVA with post hoc
Tukey’s multiple comparisons test (n = 241). (B) Median (±IQR) starting dose of Gonal F/kg is positively associated with the proportion of antral follicles recruited by
the final ultrasound scan during controlled ovarian stimulation. Categories were compared by the Kruskal-Wallis test with post hoc Dunn’s multiple comparisons test (n
= 324). (C) Median (±IQR) starting dose of rFSH adjusted for weight (iU/kg) is associated with the proportion of antral follicles that result in a mature oocyte being
retrieved. Categories were compared by the Kruskal-Wallis test with post hoc Dunn’s multiple comparisons test (n = 324). (D) Mean (±SD) of the proportion of
12–19mm follicles at the final scan is positively associated with categories of starting rFSH dose adjusted for body weight. Categories were compared by one-way
ANOVA with post hoc Tukey’s multiple comparisons test (n = 324). (E) Median (±IQR) of the proportion of 12–19mm follicles at the final scan as a function of the
antral follicle count is positively associated with categories of starting rFSH dose adjusted for body weight. Categories were compared by the Kruskal-Wallis test with
post hoc Dunn’s multiple comparisons test (n = 324). (F) Median (±IQR) of the proportion of 12–19mm follicles at the final scan as a function of the antral follicle
count is positively associated with categories of unadjusted starting rFSH dose. Categories were compared by the Kruskal-Wallis test with post hoc Dunn’s multiple
comparisons test (n = 324). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
treatment (Figure 1C). To achieve the same median follicle size
after 5 days of stimulation, a higher dose of rec rFSH was needed
if AMH levels were <40 pmol/L in comparison to those with
higher AMH levels (≥40 pmol/L; Supplemental Figure 1A).
Stratifying patients by screening serum FSH level did not
improve prediction of serum FSH level, suggesting that measured
serum FSH level predominantly represents exogenous rFSH
dosing (Supplemental Figure 1B). Serum FSH levels were
not altered by GnRH antagonist administration (p = 0.937;
Supplemental Figure 1C), whereas serum LH levels decrease by
∼50% (Supplemental Figure 1D; p < 0.0001).
Recombinant FSH and Follicular Growth
In patients predicted to be “good responders” (aged 18–34 years
and AFC >15), median follicle size following 5 days of treatment
was associated with weight-adjusted rFSH dose (Figure 2A). The
proportion of antral follicles recruited by the final ultrasound
scan during stimulation was also increased with dose of rFSH
(Figure 2B), as was the number of mature oocytes expressed as
a proportion of antral follicle count (Figure 2C). The proportion
of follicles that were within the range for follicle sizemost likely to
yield a mature oocyte on day of trigger (12–19mm in diameter)
significantly increased with starting dose of rFSH (Figure 2D).
Furthermore, the number of follicles of 12–19mm in diameter on
the day of trigger expressed as a proportion of the AFC increased
with weight-adjusted dose of FSH (Figure 2E), with greater
discrimination than with absolute rFSH doses (Figure 2F).
Median follicle size after 5 days of rFSH was a useful measure
of ovarian response, positively predicting median follicle size on
day 7 (r2 = 0.58, p < 0.0001; Supplemental Figure 2A), then in
turn on day 9 (r2 = 0.62, p < 0.0001; Supplemental Figure 2B),
and thus time to oocyte maturation trigger (r2 = 0.22, p< 0.0001;
Supplemental Figure 2C). The dose-response relationship was
also apparent in patients considered intermediate responders
(either AFC≤15 or age ≥35 years) (Supplemental Figure 3), but
was lost in patients were predicted to be “poorer responders”
receiving doses more than 2.25 iU/kg (Supplemental Figure 4).
Multivariate linear regression models were used to investigate
the relationship between rFSH dose and median follicle size
(Table 2) and the proportion of antral follicles recruited
(Table 3), adjusted for relevant baseline variable factors. Starting
rFSH dose (IU/kg) significantly predicted day 5 median follicle
size when adjusted for age, total AFC and pre-treatment serum
FSH level (r2 = 0.152, p < 0.00001, n = 630; Table 2). Starting
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TABLE 2 | Median follicle size after 5 days.
Variable Coefficient (β) p-value
Starting gonal F/kg 0.29 0.001
Antral follicle count −0.02 0.001
Pre-treatment screening FSH −0.001 0.75
Age 0.023 0.11
Constant 7.27 0.0001
Multivariate linear regression analysis of median follicle size on day 5 of rFSH treatment
and starting Gonal F dose per kg, adjusted for antral follicle count (AFC), age, and
pre-treatment serum FSH level (n = 630); r2 = 0.152, p < 0.0001.
rFSH dose (IU/kg) also predicted the proportion of antral follicles
recruited by the final scan when adjusted for age, total AFC and
pre-treatment serum FSH level (r2 = 0.147, p < 0.00001, n =
1,027; Table 3).
Starting Dose of rFSH and Variability of
Follicle Size by Day of Trigger
An increased proportion of follicles of 12–19mm on the day
of oocyte maturation trigger was associated with more mature
oocytes retrieved (Figure 3A) (22). Median follicle size of 14–
16mm on day of oocyte maturation trigger was associated
with the highest proportion of follicles being sized between 12
and 19mm (Supplemental Figure 1E). The dose of rFSH was
altered in some patients during the cycle if follicular growth
was not as anticipated. Patients who required an increase in
the average dose of rFSH by more than 5% compared to the
starting dose, had increased variability of follicle size with a
lower proportion of follicles within 12–19mm on the final
ultrasound scan before trigger (Figure 3B), and fewer mature
oocytes retrieved (Figure 3C).
Serum Estradiol as a Marker of Follicular
Response
Serum estradiol measurement on the day of final scan is
predictive of the number of mature oocytes retrieved (Figure 4A,
r2 = 0.17, p < 0.0001) and the cumulative sum of all follicle sizes
on the final scan before oocyte maturation trigger (Figure 4B,
r2 = 0.30, p < 0.0001). The cumulative sum of follicle sizes is
a better predictor of the number of mature oocytes retrieved than
serum estradiol on the day of the final scan (Figure 4C, r2 =
0.40, p < 0.0001). However, as previously reported, the number
of follicles sized between 12 and 19mm is a better predictor still
of the number of mature oocytes retrieved (Figure 4D, r2 = 0.44,
p < 0.0001) (22).
Serum LH was positively associated with serum estradiol
both after 5 days of rFSH treatment (Supplemental Figure 5A)
and on the final morning before oocyte maturation trigger
administration (Supplemental Figure 5B). A higher serum LH
was associated with a greater BMI both before commencement of
the GnRH antagonist on day 5 of rFSH treatment (p < 0.0001)
(Supplemental Figure 5C) and 2 days thereafter (p = 0.0015;
Supplemental Figure 5D).
TABLE 3 | Proportion of antral follicles recruited.
Variable Coefficient (β) p-value
Starting gonal F/kg 0.09 0.0001
Antral follicle count −0.01 0.0001
Pre-treatment screening FSH −0.001 0.94
Age −0.01 0.23
Constant 1.4946 0.0001
Multivariate linear regression analysis of proportion of antral follicles recruited by final
ultrasound scan before administration of oocyte maturation trigger and starting rFSH dose
per kg, adjusted for antral follicle count (AFC), age, and pre-treatment serum FSH level (n
= 774); r2 = 0.147, p < 0.0001.
DISCUSSION
We investigated the relationship between rFSH dose and follicle
growth in data from 1,034 IVF cycles. Preliminary analysis
revealed that recombinant FSH dose adjusted for body weight
(IU per kg) was associated with steady-state serum FSH levels
and median follicle size following 5 days of rFSH treatment.
Median follicle size after 5 days of rFSH was a useful measure,
positively predicting median follicle size on subsequent scans
and thus time to administration of oocyte maturation trigger.
Once antral follicles are recruited to grow, they become less FSH-
dependent for their continued growth and accrue LH receptors
(29). Indeed, this is also reflected by the isoform of FSH changing
during the follicular phase to become more acidic and less
bioactive (30).
Antral follicles represent a pool of follicles capable of being
recruited to grow if sufficient FSH exposure is provided. The
differential sensitivity of individual antral follicles within a
cohort, enables the success of step-up protocols for inducing
mono-follicular growth in ovulation induction cycles, by
gradually achieving the minimum threshold for growth of the
most sensitive follicles (31). In the current study, the starting
rFSH dose predicted the proportion of antral follicles that were
recruited by the final scan before administration of the trigger of
oocyte maturation. In some women, more follicles were recruited
by the end of stimulation than pre-stimulation antral follicles.
Possible explanations for this observation could include that
secondary waves of antral follicles were recruited later during the
stimulation phase, or alternatively that measurement error in the
quantification of antral follicle count could have underestimated
the true antral follicle count.
During a multi-variate analysis, variables identified as being
relevant were consistent with those identified to influence oocyte
number in the CONSORT algorithm (BMI, AFC, age) (32, 33).
Accordingly, these data enable reproductive endocrinologists to
individualize follicle recruitment based on treatment aims for an
individual patient. For example, follicle recruitment in a woman
at high risk of OHSS can be decreased if hCG is to be used as the
trigger of oocyte maturation, as per the intention of the PIVET
protocol (11). Oocyte number expressed as a proportion of antral
follicle count was associated with starting rFSH dose, in keeping
with data from other FSH preparations (34). Alternatively, these
data can inform rFSH dosing to maximize follicular recruitment,
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FIGURE 3 | Effect of starting rFSH dose on variability in follicle size on day of trigger. (A) Median (±IQR) of the number of mature oocytes is presented by proportion of
follicles sized 12–19mm at the final ultrasound scan prior to administration of oocyte maturation trigger. Categories were compared by the Kruskal-Wallis test with
post hoc Dunn’s multiple comparisons test (n = 1029). (B) Increasing an insufficient starting rFSH dose during the cycle resulted in a reduced proportion of follicles
sized 12–19mm (n = 1034). Mean (±SD) is presented. Categories were compared by one-way ANOVA with post hoc Tukey’s multiple comparisons test. (C)
Increasing an insufficient starting rFSH dose during the cycle resulted in fewer mature oocytes retrieved. Median (±IQR) number of mature oocytes is presented.
Categories were compared by the Kruskal-Wallis test with post hoc Dunn’s multiple comparisons test (n = 1034). **p < 0.01, ***p < 0.001, ****p < 0.0001.
FIGURE 4 | Relationship between serum estradiol, follicle size and number of mature oocytes retrieved. (A) Serum estradiol (pmol/L) on the day of the final scan
before administration of the trigger of oocyte maturation predicts the number of mature oocytes subsequently retrieved (n = 419; r2 = 0.17, P <0.0001). (B) Serum
estradiol (pmol/L) at the final scan before administration of the trigger of oocyte maturation also correlates with the cumulative sum of follicle sizes (mm) of all follicles
by ultrasound scan (n = 419; r2 = 0.30, P < 0.0001). Whilst the sum of follicle sizes on the final scan before administration of oocyte maturation trigger predicted the
number of mature oocytes retrieved (C, n = 1034; r2 =0.40, P < 0.0001), this was better predicted by the number of follicles sized 12–19mm in diameter (D, n =
1031; r2 = 0.44, P < 0.0001).
if an alternate trigger to hCG is used to induce oocyte maturation
in order to mitigate the risk of OHSS (35).
In accordance with the published literature, we observed
that the dose-response relationship was lost in anticipated poor
responders (AFC ≤ 15 & age ≥ 35 years) receiving doses
of rFSH over 2.25iU/kg (36, 37). Thus, 1.5 iU/kg can be
regarded as a low dose of rFSH and 2.25 iU/kg as an upper
threshold dose, beyondwhichminimal further follicular response
is anticipated, in keeping with similar data using follitropin
delta (38).
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Serum estradiol is used as a marker of adequate ovarian
response by some clinicians, and rFSH dose increased if serum
estradiol is deemed suboptimal, even if follicle growth appears
adequate. However, this relationship appears to be indirect;
serum estradiol at the end of stimulation was correlated with the
cumulative sum of follicle sizes on the day of trigger, as well as the
number of mature oocytes subsequently retrieved. Nevertheless,
the number of follicles sized 12–19mm at the end of stimulation
was a better predictor of the number of mature oocytes retrieved
than serum estradiol level (Figure 4) (22).
We investigated the impact of dose-adjustment during
stimulation. We hypothesized that an insufficient dose of rFSH
could lead to recruitment of the most sensitive follicles, whilst
the majority of follicles would remain dormant. A subsequent
dose-increase would recruit another wave of follicles that would
therefore result in increased variability of follicle size by the end
of stimulation. We observed that a lower starting rFSH dose
reduced the proportion of follicles sized 12–19mm at the end
of stimulation in keeping with data using a novel human rFSH
(39) and with our previous data (22). Furthermore, the need to
increase the mean dose of rFSH by more than 5% of the starting
dose reduced the proportion of follicles of 12–19mmat the end of
stimulation, and this was associated with 5 fewer mature oocytes.
The rFSH preparation studied (Gonal F) has a terminal half-
life of 1 day and reaches steady state levels after 3–4 days (40).
Thus, in some units, a higher dose of rFSH is used for the first
few days of stimulation to rapidly achieve adequate FSH levels
and recruit all available follicles, before the dose is reduced to
maintenance levels (step-down protocol). Our data is consistent
with such an approach being logical in aiming to recruit follicles
as a closely clustered cohort at the beginning of stimulation, thus
reducing variability in follicle size and optimizing the action of
the oocyte maturation trigger (22).
It has been established that there is insufficient evidence to
suggest that rFSH dose significantly impacts live birth rates (37).
This is logical, since providing that at least one good quality
embryo is formed, there is no biological rationale for a difference
in live birth rate due to rFSH dose (37, 41, 42). However, a
higher rFSH dose was associated with a reduced chance of cycle
cancellation due to insufficient ovarian response, albeit at the
expense of an increased risk of OHSS (37, 41, 42). Importantly
in predicted high response women, there remained significant
proportions of women experiencing either poor or hyper-
response at both doses examined (100IU rFSH: poor-response
34%, hyper-response 12%; 150IU of rFSH: poor-response 8%,
hyper-response 38%) (41).
Strengths of our study are the inclusion of a large number of
cycles examined at a single center, thereby limiting heterogeneity
due to protocol differences amongst different reproductive
endocrinology treatment centers. Furthermore, monitoring was
conducted using the same ultrasound machines (Toshiba Xario
Prime, Crawley, UK) and no more than 9 experienced IVF
practitioners measured follicle size during the period of the study.
Only data from cycles that used rFSH (Gonal F) alone were
included, thus limiting variability due to other FSH preparations.
Limitations of the study include its retrospective design, and
that due to heterogeneity in day of monitoring ultrasound
scans, not all cycles could be used in every analysis. Serum
FSH, LH, and AMH levels were only measured for a subset
of cycles and thus any benefit to using serum FSH level over
rFSH dose adjusted for weight could not be ascertained. Serum
AMH and AFC both have similar diagnostic accuracy as ovarian
response markers (43), although AMH may be considered
as more reproducible than AFC between centers (44). The
majority of analyses assessed parameters of follicle growth and
were thus unaffected by the trigger used, as these outcomes
preceded administration of the trigger. For data which included
the number of mature oocytes retrieved, sensitivity analyses
confirmed that results were comparable regardless of trigger
used. Prospective studies prescribing rFSH using a weight-based
regimen and evaluating follicular growth are indicated to further
overcome the limitations of the retrospective design. The use
of 3-D ultrasound to track follicular development in future
prospective studies could more accurately relate rFSH dose to
follicular growth.
To conclude, we have identified a dose-response for starting
rFSH dose to median follicle size following 5 days of treatment,
and to the proportion of antral follicles recruited. Our data
suggests that commencing stimulation with a sufficient rFSH
dose from the start of the cycle reduces variability in follicle
size to thus maximize the number of mature oocytes retrieved.
Consistent with published data suggesting an upper threshold
to useful FSH dosing, we find minimal further increase in
response beyond a rFSH dose of 2.25iU/kg (37). These data reveal
important physiological information on FSH requirements for
follicular growth. In addition, these findings inform clinicians
in selecting a suitable starting rFSH dose for their patients that
is tailored to the treatment aims for that individual. However,
future research is required to further evaluate the dose-response
relationships identified in this study.
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Supplemental Figure 1 | (A) Median starting dose of rFSH adjusted for weight
(iU/kg) is presented by categories of median follicle size after 5 days of rFSH,
stratified by pre-treatment serum AMH level (either AMH <40 pmol/L or AMH
≥40pmol/L) (n = 147). (B) Simple linear regression of serum FSH level (iU/L) on
day 4–5 of rFSH treatment by starting rFSH dose per kg (iU/kg) stratified by
pre-treatment follicular phase serum FSH level (iU/L); (n = 166). There is no
difference in relationship between serum FSH level at 4–5 days after starting rFSH
treatment and starting dose of rFSH per kg when stratifying by pre-treatment
serum FSH level. (C,D) Serum FSH (B) (iU/L), and serum LH (iU/L) (C) are
presented, before starting GnRH antagonist treatment (day 5 of cycle), and 2 days
after starting GnRH antagonist treatment (day 7); (n = 166) (2 outlying data points
not shown for serum LH). Paired values of serum FSH and of serum LH were
compared by the Wilcoxon signed rank test. GnRH antagonist administration
caused no significant change in serum FSH levels (p = 0.937) (B), but a significant
reduction in the serum LH level (p < 0.0001) (C). (E) Median follicle size (median
±IQR) on the day of oocyte maturation trigger is associated with the proportion of
12–19mm follicles at the final scan (n = 175). Categories were compared by the
Kruskal-Wallis test with post hoc Dunn’s multiple comparisons test.
∗∗∗∗p < 0.0001.
Supplemental Figure 2 | Median follicle size after 5 days of rFSH treatment
predicts median follicle size on subsequent scans (A,B) and thus the day of
oocyte maturation trigger (C) by simple linear regression. (A) Median follicle size
(mm) on day 5 and on day 7 of rFSH treatment (n = 351): Day 7 median follicle
size = 1.066∗Day 5 median follicle size + 1.45, r2 = 0.58, p < 0.0001. (B)
Median follicle size (mm) on day 7 and day 9 of rFSH treatment (n = 260): Day 9
median follicle size = 0.997∗Day 7 median follicle size + 2.01, r2 = 0.62, p <
0.0001. (C) Day of oocyte maturation trigger by median follicle size (mm) on day 5
of rFSH treatment; (n = 632). Day of oocyte maturation trigger = −0.67∗Day 5
median follicle size + 15.94, r2 = 0.22; p < 0.0001.
Supplemental Figure 3 | Follicle growth in a subset of predicted “intermediate
responders” (either AFC > 15 or age 18–35 years). Median follicle size after 5
days of rFSH treatment (A), the proportion of the antral follicle count (AFC)
recruited to grow (B), and the proportion of the antral follicles that yield mature
oocytes (C) increase with starting dose of rFSH (IU per kg). (A) There is an
association between starting rFSH dose (iU/kg) and median follicle size after 5
days of rFSH treatment. Mean (±SD) is presented and categories were compared
by one-way ANOVA with post hoc Tukey’s multiple comparisons test (n = 193).
(B) There is an association between starting rFSH dose (iU/kg) and the proportion
of antral follicles recruited to grow by the final scan (n = 323). Median (±IQR) is
presented and categories were compared by the Kruskal-Wallis test with post hoc
Dunn’s multiple comparisons test (1 outlier was not presented). (C) There is an
association between starting rFSH dose (iU/kg) and the proportion of 12–19mm
follicles at the final scan (n = 327). Mean (±SD) is presented and categories were
compared by one-way ANOVA with Tukey’s multiple comparisons test. (D) There
is an association between starting rFSH dose (iU/kg) and the proportion of antral
follicles that yield a mature oocyte (n = 323). Median (±IQR) is presented.
Categories were compared by the Kruskal-Wallis test with Dunn’s multiple
comparisons test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Supplemental Figure 4 | Follicle growth in response to rFSH in a subset of
predicted poorer responders (AFC≤15 and age≥35 years). (A) No significant
differences were found between categories of starting rFSH dose (iU/kg) and
median follicle size after 5 days (n = 45). Mean (±SD) is presented and categories
were compared by one-way ANOVA with post hoc Tukey’s multiple comparisons
test. (B) No significant differences were observed between starting rFSH dose
(iU/kg) and the proportion of the antral follicle count (AFC) recruited to grow (n =
120). Median (±IQR) is presented and categories were compared by the
Kruskal-Wallis test with post hoc Dunn’s multiple comparisons test. (C) No
significant differences were observed between starting rFSH dose (iU/kg) and the
proportion of 12–19mm follicles at the end of stimulation (n = 120). Mean (±SD) is
presented and categories were compared by one-way ANOVA with post hoc
Tukey’s multiple comparisons test. (D) No significant differences were observed
between starting rFSH dose (iU/kg) and the proportion of antral follicles that yield a
mature oocyte (n = 120). Median (±IQR) is presented and categories were
compared by the Kruskal-Wallis test with post hoc Dunn’s multiple
comparisons test.
Supplemental Figure 5 | (A,B) Both serum LH after 5 days of rFSH treatment (A;
n = 166) and serum LH on the final morning before oocyte maturation trigger
administration (B; n = 164) are positively associated with serum estradiol after 5
days of rFSH treatment. Median (±IQR) is presented and categories were
compared by the Kruskal-Wallis test with post hoc Dunn’s multiple comparisons
test (n = 166). (C,D) A lower body mass index (BMI) is associated with lower
serum LH levels both before (C; n = 167) and after (D; n = 131) administration of
GnRH antagonist. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001. Median (±IQR) is
presented and categories were compared by the Mann Whitney U test (n = 167).
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